Investment Thesis
Sonoma Pharmaceuticals faces significant operational headwinds with flat revenue growth (0% YoY) and substantial net losses of $3.2M. Despite improving loss trends YoY, the company is burning $4.1M in free cash flow annually with only $2.4M in cash reserves, creating a critical cash runway concern within 6-9 months absent capital raises or operational improvements.
Strengths
- Improving profitability trajectory - net loss narrowing 8.2% YoY and EPS improving 32.3% YoY indicates operational traction
- Healthy gross margin of 38% demonstrates product economics are sound if scale can be achieved
- Strong liquidity position with 2.50x current ratio and 1.75x quick ratio, plus minimal debt burden
Risks
- Stagnant revenue growth at 0% YoY threatens long-term viability and suggests market adoption challenges
- Negative free cash flow of $4.1M annually with only $2.4M cash reserves creates acute liquidity risk within 6-9 months
- Operating losses of $2.5M indicate inability to achieve profitability at current revenue levels; requires either 30%+ revenue growth or significant cost reduction
- Zero insider buying activity in past 90 days may signal lack of confidence from management
Key Metrics to Watch
- Quarterly revenue growth - must return to positive territory to validate turnaround
- Operating cash flow trend - critical to extend cash runway and demonstrate path to breakeven
- Cash balance and burn rate - watch for announcements of capital raises or financing activities
- Gross margin sustainability - ensure product mix and pricing remain stable during scaling
Financial Metrics
Revenue
19.5M
Net Income
-3.2M
EPS (Diluted)
$-1.89
Free Cash Flow
-4.1M
Total Assets
14.0M
Cash
2.4M
Profitability Ratios
Gross Margin
38.0%
Operating Margin
-12.6%
Net Margin
-16.3%
ROE
-102.6%
ROA
-22.7%
FCF Margin
-21.1%
Balance Sheet & Liquidity
Current Ratio
2.50x
Quick Ratio
1.75x
Debt/Equity
0.00x
Debt/Assets
77.8%
Interest Coverage
-2,461.00x
Long-term Debt
15.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-06-18T07:20:51.365153 |
Data as of: 2026-03-31 |
Powered by Claude AI